世界の臨床腫瘍学次世代シーケンシング(NGS)市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV11397)
◆英語タイトル:Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV11397
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:131
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは臨床腫瘍学次世代シーケンシング(NGS)の世界市場について調査・分析した資料です。種類別(NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析)の市場規模、用途別(学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別臨床腫瘍学次世代シーケンシング(NGS)の競争状況、市場シェア
・世界の臨床腫瘍学次世代シーケンシング(NGS)市場:種類別市場規模 2015年-2020年(NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析)
・世界の臨床腫瘍学次世代シーケンシング(NGS)市場:種類別市場規模予測 2021年-2026年(NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析)
・世界の臨床腫瘍学次世代シーケンシング(NGS)市場:用途別市場規模 2015年-2020年(学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体)
・世界の臨床腫瘍学次世代シーケンシング(NGS)市場:用途別市場規模予測 2021年-2026年(学術・臨床研究、病院・クリニック、製薬・バイオ技術事業体)
・北米の臨床腫瘍学次世代シーケンシング(NGS)市場分析:米国、カナダ
・ヨーロッパの臨床腫瘍学次世代シーケンシング(NGS)市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの臨床腫瘍学次世代シーケンシング(NGS)市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の臨床腫瘍学次世代シーケンシング(NGS)市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの臨床腫瘍学次世代シーケンシング(NGS)市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Illumina、Roche、Agilent Technologies、Knome、Genomatix Software、GATC Biotech、Oxford Nanopore Technologies、Macrogen、Life Technologies、DNASTAR、Exosome Diagnostics、Biomatters、CLC Bio、BGI、Qiagen、Perkin Elmer、Pacific Bioscience、Partek、GnuBIO、Foundation Medicine、Paradigm、Caris Life Sciences、Myriad Genetics
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.

Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
The global Clinical Oncology Next Generation Sequencing (NGS) market size is projected to reach US$ 782.8 million by 2026, from US$ 704.7 million in 2020, at a CAGR of 10.6%% during 2021-2026.

Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics

Market segment by Type, the product can be split into
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Market segment by Application, split into
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
1.4 Market by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2026
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2015-2026)
2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2015-2020)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market Growth Strategy
2.3.6 Primary Interviews with Key Clinical Oncology Next Generation Sequencing (NGS) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Market Size
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2015-2020)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2015-2020)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2019
3.3 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.4 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.5 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2015-2020)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in North America (2019-2020)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe (2019-2020)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

8 China
8.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China (2019-2020)
8.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
8.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan (2019-2020)
9.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
9.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
10.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

11 India
11.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India (2019-2020)
11.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
11.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2015-2020)
12.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America (2019-2020)
12.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2015-2020)
12.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Illumina
13.1.1 Illumina Company Details
13.1.2 Illumina Business Overview
13.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020))
13.1.5 Illumina Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Agilent Technologies
13.3.1 Agilent Technologies Company Details
13.3.2 Agilent Technologies Business Overview
13.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.3.5 Agilent Technologies Recent Development
13.4 Knome
13.4.1 Knome Company Details
13.4.2 Knome Business Overview
13.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.4.5 Knome Recent Development
13.5 Genomatix Software
13.5.1 Genomatix Software Company Details
13.5.2 Genomatix Software Business Overview
13.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.5.5 Genomatix Software Recent Development
13.6 GATC Biotech
13.6.1 GATC Biotech Company Details
13.6.2 GATC Biotech Business Overview
13.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.6.5 GATC Biotech Recent Development
13.7 Oxford Nanopore Technologies
13.7.1 Oxford Nanopore Technologies Company Details
13.7.2 Oxford Nanopore Technologies Business Overview
13.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.7.5 Oxford Nanopore Technologies Recent Development
13.8 Macrogen
13.8.1 Macrogen Company Details
13.8.2 Macrogen Business Overview
13.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.8.5 Macrogen Recent Development
13.9 Life Technologies
13.9.1 Life Technologies Company Details
13.9.2 Life Technologies Business Overview
13.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.9.5 Life Technologies Recent Development
13.10 DNASTAR
13.10.1 DNASTAR Company Details
13.10.2 DNASTAR Business Overview
13.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
13.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
13.10.5 DNASTAR Recent Development
13.11 Exosome Diagnostics
10.11.1 Exosome Diagnostics Company Details
10.11.2 Exosome Diagnostics Business Overview
10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.11.5 Exosome Diagnostics Recent Development
13.12 Biomatters
10.12.1 Biomatters Company Details
10.12.2 Biomatters Business Overview
10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.12.5 Biomatters Recent Development
13.13 CLC Bio
10.13.1 CLC Bio Company Details
10.13.2 CLC Bio Business Overview
10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.13.5 CLC Bio Recent Development
13.14 BGI
10.14.1 BGI Company Details
10.14.2 BGI Business Overview
10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.14.5 BGI Recent Development
13.15 Qiagen
10.15.1 Qiagen Company Details
10.15.2 Qiagen Business Overview
10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.15.5 Qiagen Recent Development
13.16 Perkin Elmer
10.16.1 Perkin Elmer Company Details
10.16.2 Perkin Elmer Business Overview
10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.16.5 Perkin Elmer Recent Development
13.17 Pacific Bioscience
10.17.1 Pacific Bioscience Company Details
10.17.2 Pacific Bioscience Business Overview
10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.17.5 Pacific Bioscience Recent Development
13.18 Partek
10.18.1 Partek Company Details
10.18.2 Partek Business Overview
10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.18.5 Partek Recent Development
13.19 GnuBIO
10.19.1 GnuBIO Company Details
10.19.2 GnuBIO Business Overview
10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.19.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.19.5 GnuBIO Recent Development
13.20 Foundation Medicine
10.20.1 Foundation Medicine Company Details
10.20.2 Foundation Medicine Business Overview
10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.20.5 Foundation Medicine Recent Development
13.21 Paradigm
10.21.1 Paradigm Company Details
10.21.2 Paradigm Business Overview
10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.21.5 Paradigm Recent Development
13.22 Caris Life Sciences
10.22.1 Caris Life Sciences Company Details
10.22.2 Caris Life Sciences Business Overview
10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.22.5 Caris Life Sciences Recent Development
13.23 Myriad Genetics
10.23.1 Myriad Genetics Company Details
10.23.2 Myriad Genetics Business Overview
10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
10.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2015-2020)
10.23.5 Myriad Genetics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Illumina、Roche、Agilent Technologies、Knome、Genomatix Software、GATC Biotech、Oxford Nanopore Technologies、Macrogen、Life Technologies、DNASTAR、Exosome Diagnostics、Biomatters、CLC Bio、BGI、Qiagen、Perkin Elmer、Pacific Bioscience、Partek、GnuBIO、Foundation Medicine、Paradigm、Caris Life Sciences、Myriad Genetics

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の臨床腫瘍学次世代シーケンシング(NGS)市場2026:インサイト・予測(Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。